Connect with us

Hi, what are you looking for?

Stock

23andMe considers selling its telehealth unit Lemonaid

Investing.com — Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to Business Insider. The company, which has faced financial difficulties, originally acquired the virtual care startup in 2021 for $400 million in a cash and stock deal.

The stock value of 23andMe has seen a significant drop following a data breach in 2023 that exposed numerous customer accounts. The potential sale of Lemonaid Health appears to be part of the company’s strategy to navigate its current financial situation.

When 23andMe first purchased Lemonaid, it expressed an intention to offer personalized telemedicine care, using its genetic data collection to inform this care. However, it remains unclear how advanced the company’s efforts to sell Lemonaid Health are at this stage, as 23andMe has not responded to multiple requests for comment.

Lemonaid Health’s potential buyer remains unknown as the company has not disclosed any further details about this possible sale.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

    You May Also Like

    Latest News

    A group of more than 60 former Democratic and Republican attorneys general sent a new letter to Senate leaders Thursday urging the confirmation of...

    Stock

    Investing.com — RBC Capital Markets in a note dated Thursday has downgraded Swatch Group (SIX:UHR) to an “underperform” rating, citing structural and cyclical challenges...

    Stock

    Investing.com — Universal Music Group (AS:UMG) and Spotify (NYSE:SPOT) have announced a new multi-year deal for recorded music and publishing, the companies announced in...

    Stock

    By Rocky Swift TOKYO (Reuters) -Japan’s Fuji Media said on Monday its chairman and the head of its TV unit would step down immediately...



    Disclaimer: Techreportdiversity.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Techreportdiversity.com